Amarin Corp Plc (AMRN)

[eightisenough]

All investors should be ecstatic that we have 3 great arguments to win the case. Markman's blog calls them as:

(1) The Cyclobenzaprine Argument;
(2) The Weighing of the Secondary Considerations Argument; and
(3) The Two Patient Populations Argument.

Markman himself makes holes in each one to anticipate the generics response, but as the comments there point out--those are weak attacks. Just need patience for the verdict. Ignore amrn until sept/dec.

https://www.markmanadvisors.com/blog/2020/5/19/amarin-what-does-amarins-opening-appellate-brief-say